Ultrasound-guided long-term platelet-rich plasma injections for moderate-to-severe knee osteoarthritis: a case report Authors: Iokieng Iao, Na Li, Chongleong Lao, Yuefei Guo, Xiaomei Wei, Lukun Guo, Ying Lu, Juanjuan He Published: 2026 ABSTRACT BackgroundModerate-to-severe knee osteoarthritis (KOA) involves progressive cartilage degeneration, meniscal tears, synovitis, and osteophyte formation, leading to persistent pain and functional impairment. Conventional therapies often provide inadequate relief. While platelet-rich plasma (PRP) injections have emerged as a promising regenerative treatment, their efficacy is predominantly established in mild-to-moderate KOA, with limited benefits observed in moderate-to-severe cases.Case presentationA 57-year-old Chinese male with bilateral moderate-to-severe knee osteoarthritis was treated with ultrasound-guided PRP injections. Over a 15-month period, he received a total of 34 bilateral intra-articular injections. At the final follow-up, both NRS and WOMAC scores were significantly reduced, concurrent with enhanced joint function and quality of life. Follow-up MRI revealed improvements in intra-articular structures, including the meniscal morphology, as well as a reduction in inflammation-related parameters, such as bone marrow edema, joint effusion, infrapatellar fat pad swelling, and synovitis.ConclusionsThis study concludes that ultrasound-guided long-term PRP injection is a safe and effective therapeutic strategy for moderate-to-severe knee osteoarthritis. It provides significant relief from pain, functional improvement, enhanced quality of life, and yields objective imaging evidence of joint improvement on MRI. Introduction Knee osteoarthritis (KOA) is a prevalent degenerative joint disease and its incidence is progressively increasing due to the aging population and rising rates of obesity [1]. Moderate-to-severe KOA is characterized by distinct pathological and clinical features, including progressive cartilage degeneration, meniscal damage, synovial hyperplasia, joint effusion, and marginal osteophyte formation [2]. Clinically, it is characterized by persistent severe pain and substantial loss of joint function, presenting significant therapeutic challenges. Among current treatment strategies, PRP injection has emerged as a promising regenerative therapy for KOA [3]. PRP is characterized by a high concentration of autologous platelets and fibrin, which are rich in growth factors, such as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). Upon intra-articular injection, these platelets become activated and release this spectrum of growth factors, which stimulate cellular proliferation and matrix regeneration. Concurrently, the fibrin network forms a supportive scaffold for tissue repair [4]. Through these mechanisms, PRP facilitates cartilage repair, modulates synovial inflammation, and alleviates pain [5]. While previous studies have consistently demonstrated the efficacy of PRP in managing mild-to-moderate KOA, its therapeutic value in moderate-to-severe KOA remains controversial. This discrepancy is likely attributable to heterogeneity in disease classification criteria and, more importantly, considerable variability in PRP treatment protocols particularly concerning the number of injections, their frequency, and the intervals between them. Herein, we present a case of bilateral moderate-to-severe KOA (Outerbridge grades 3–4, Kellgren–Lawrence grade 3) evaluated via MRI and X-ray, in a patient who underwent a standardized, extended regimen of ultrasound-guided PRP injections over a 15-month period. This protocol resulted in significant symptomatic and functional improvement without any adverse events, providing valuable clinical evidence to support the potential of optimized, long-term PRP treatment strategies for moderate-to-severe KOA. The details of this case are reported below. Case presentation A 57-year-old Chinese male was evaluated in the Rehabilitation Medicine outpatient clinic of the Third Affiliated Hospital of Sun Yat-sen University for a recent exacerbation of chronic bilateral knee pain. His symptoms began 7 years ago as intermittent pain without an obvious cause. Initial radiographs at that time revealed degenerative changes in both knees (Kellgren–Lawrence grade 3), for which he received no systemic treatment. In January 2024, his symptoms worsened significantly, characterized by persistent pain that aggravated after activity, with a severity of 7–8 on the Numerical Rating Scale (NRS), and MRI revealed Outerbridge grade 3–4 changes. The patient also reported audible crepitus, limited joint movement, and difficulty with squatting, rising from a chair, and ascending/descending stairs (requiring handrail support), which significantly impaired his ambulation. No joint redness, warmth, night pain, or systemic fever was reported. His medical history consisted of well-controlled hypertension (on amlodipine) and hyperlipidemia (on atorvastatin) for over 3 years. Physical examination revealed mild bilateral knee swelling, most notable in the suprapatellar bursae, without elevated skin temperature. Tenderness was noted around the patella and over both medial and lateral joint lines. The patellar grind test was positive, while the ballottement test was negative. McMurray's test elicited pain. Active range of motion was significantly limited: flexion to 90° and extension to 0°. Dorsalis pedis pulses were palpable, and distal sensation and motor function were intact. Muscle strength was graded as 5-/5 in both lower extremities. Magnetic resonance imaging (MRI) of both knees performed before treatment, revealed severe degenerative changes: Left knee: Full-thickness chondral loss (Outerbridge grade IV) over the femoral condyle with subchondral bone edema; Outerbridge grade III chondral lesion of the patella; a grade III horizontal tear of the posterior horn of the medial meniscus; a discoid lateral meniscus; joint effusion with synovial hyperplasia; and thickening of the medial synovial plica. Right knee: Full-thickness chondral loss (Outerbridge grade IV) over the femoral condyle with subchondral bone edema; Outerbridge grade III chondral lesion of the patella; a discoid lateral meniscus; and joint effusion involving the suprapatellar.. Final Diagnoses: 1. Bilateral knee osteoarthritis; 2. Hypertension; 3. Hyperlipidemia. Treatment methods PRP injection regimen: The patient, who has a medical background, held a strong personal belief in the regenerative potential of PRP therapy. He persistently requested PRP injections as a treatment modality. This led to a high-frequency, long-term course of PRP injections, reflecting his autonomous treatment preferences rather than the institution's standard protocol. Therefore, the patient received a total of 34 bilateral knee PRP injections between February 2024 and May 2025. The treatment course consisted of an initial series of weekly injections for 4 weeks, followed by biweekly administrations thereafter. PRP preparation: Using a secondary centrifugation method, ① four 10 mL EDTA-anticoagulated blood collection tubes were obtained. In accordance with standard venipuncture procedures, 40 mL of peripheral blood was collected from each patient, and the PLT concentration was measured. The samples were subsequently centrifuged at 500 × g for 8 min via a fixed-angle rotor. ② The supernatant plasma obtained from the first centrifugation was transferred into a sterile centrifuge tube via a pipette. The mixture was mixed gently, and then the platelet concentration and plasma volume were measured. The mixed plasma from step ② was subsequently centrifuged at 1900 × g for 12 min with a fixed-angle rotor. Third, the platelet-poor plasma (PPP) supernatant obtained after the second centrifugation was discarded, and the lower plasma layer was retained. The platelet pellet at the bottom of the retained plasma was homogenized via a sterile pipette. The platelet concentration was measured again (approximately 1000 × 109/L). Approximately 6 mL of PRP is finally obtained, which is aspirated into a disposable syringe for clinical use. The PRP administered was a leukocyte-poor preparation (LP-PRP), and no exogenous activators (e.g., calcium chloride or thrombin) were added during the preparation process. Ultrasound-guided knee joint PRP injection: The procedure was performed according to our established protocol [6] under ultrasound guidance targeting the suprapatellar bursa. The steps were as follows: (1) the patient was placed supine with the knee maintained in full extension. A gentle quadriceps contraction was utilized to stabilize the joint. (2) A high-frequency linear-array ultrasound transducer (3–10 MHz; SonoSite S-Nerve ultrasound system) was placed transversely over the distal femur, superior to the patella, to visualize the suprapatellar bursa. (3) Following standard skin disinfection and draping, the transducer was stabilized with the non-dominant hand. Using an in-plane approach from the superolateral aspect, the needle was advanced under real-time guidance until its tip was confirmed to be within the suprapatellar bursa. The PRP was then injected slowly under direct visualization (Fig. 1).Fig. 1Ultrasound-guided injection of PRP into the knee joint. The white arrow indicated the location of the hypodermic needle, the white asterisk indicated the location of the suprapatellar bursa, and the white triangle indicated the femoral cortex Ultrasound-guided injection of PRP into the knee joint. The white arrow indicated the location of the hypodermic needle, the white asterisk indicated the location of the suprapatellar bursa, and the white triangle indicated the femoral cortex Evaluation method Clinical evaluation Clinical assessments were conducted at baseline and at 1, 3, 9, and 15 months after the treatment. The evaluation included the following domains: Pain intensity Quantified via the numerical rating scale (NRS), where scores range from 0 ("no pain") to 10 ("worst imaginable pain"). Patients select the numerical value that best represents their current pain level. Range of motion (ROM) Assess the total active motion (TAM) of the knee joint and measure the cumulative degrees of flexion and extension during active movement. Muscle strength Evaluated via the Manual Muscle Testing (MMT) system (6-point scale) for bilateral lower limbs, with lower grades indicating greater weakness (grade 0: no contraction; grade 5: normal resistance). Balance assessment Dynamic balance: The timed up and go test (TUG) records the time (seconds) required to stand from a chair, walk 3 m, and return. Static balance: The balance error scoring system (BESS) quantifies postural stability errors under 6 sensory conditions (e.g., foam surface/eyes closed). Knee function Graded by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): pain subscale: 5 items (0–20 points); stiffness subscale: 2 items (0–8 points); and physical function subscale: 17 items (0–68 points). Higher total scores (max 96) indicate worse function. Quality of life (QoL) QoL was assessed with the 12-Item Short Form Health Survey (SF-12). This instrument generates summary scores for physical and mental health components, with higher scores indicating better health-related quality of life. Laboratory and imaging examinations Routine blood tests Peripheral venous blood was collected before PRP therapy and after the complete treatment course for CBC analysis. The primary observation indicators included the white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb) level, and platelet count (PLT), with the aim of evaluating baseline platelet levels and monitoring potential adverse reactions (e.g., infection, anemia) during treatment. Magnetic resonance imaging of the knee joint Bilateral knee MRI was performed using a GE SIGNA Architect 3.0 T equipped with a dedicated knee coil. With the patient in the supine position, the following sequences were acquired: sagittal T1-weighted imaging (T1WI), and sagittal and coronal fat-suppressed proton density-weighted imaging (PDWI). These sequences were utilized to assess the articular cartilage, menisci, bone marrow edema, and joint effusion. Imaging evaluation: Two senior radiologists independently assessed the MR images and were blinded to the examination timepoints. The evaluation primarily included the following aspects: cartilage injury, which was evaluated via Outerbridge grading. For meniscus injury, the signal, morphology, and degree of tear of the meniscus were evaluated. Bone marrow edema: The location and extent of edema were recorded. Joint effusion, synovial hyperplasia, and ligament conditions. Adverse events Common PRP injection-related adverse events, including local pain, swelling, tenderness, and erythema, were monitored throughout the designated follow-up period. Therapeutic effect The patient's body mass index (BMI) remained stable throughout the study period. Clinical evaluations, however, revealed substantial improvements by the 1-month follow-up. These included significant increases in TAM and SF-12 scores, alongside significant reductions in NRS, TUG, BESS, and WOMAC scores. Furthermore, the clinical outcomes further improved significantly at the 3-, 9-, and 15-month follow-ups compared to the 1-month assessment, reinforcing the long-term benefit of the treatment (Table 1).Table 1Clinical outcome measures at baseline and during the follow-up period after PRP therapyAssessment toolBaseline1 month3 months9 months15 monthsBMI(kg/m2)21.722.422.121.721.7NRSLeft knee84321Right knee73221TAM(°)Left knee90105125135135Right knee90110130135135MMT (Grade)Left lower limb5-5555Right lower limb5-5555TUG test (seconds)Normal Speed15.311.310.59.59.1Top speed12.39.38.07.67.0BESSLeft lower limb4028252017Right lower limb3925201917WOMACLeft knee60281084Right knee5620884SF-12 (points)2438404245BMI, Body Mass Index; NRS, Numerical Rating Scale; TAM, Total Active Motion; MMT, Manual Muscle Testing; TUG, Timed Up and Go; BESS, Balance Error Scoring System; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; SF-12, 12-Item Short Form Health Survey Table 1Clinical outcome measures at baseline and during the follow-up period after PRP therapyAssessment toolBaseline1 month3 months9 months15 monthsBMI(kg/m2)21.722.422.121.721.7NRSLeft knee84321Right knee73221TAM(°)Left knee90105125135135Right knee90110130135135MMT (Grade)Left lower limb5-5555Right lower limb5-5555TUG test (seconds)Normal Speed15.311.310.59.59.1Top speed12.39.38.07.67.0BESSLeft lower limb4028252017Right lower limb3925201917WOMACLeft knee60281084Right knee5620884SF-12 (points)2438404245BMI, Body Mass Index; NRS, Numerical Rating Scale; TAM, Total Active Motion; MMT, Manual Muscle Testing; TUG, Timed Up and Go; BESS, Balance Error Scoring System; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; SF-12, 12-Item Short Form Health Survey Clinical outcome measures at baseline and during the follow-up period after PRP therapy BMI, Body Mass Index; NRS, Numerical Rating Scale; TAM, Total Active Motion; MMT, Manual Muscle Testing; TUG, Timed Up and Go; BESS, Balance Error Scoring System; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; SF-12, 12-Item Short Form Health Survey Complete blood count: As shown in Table 2, all complete blood count parameters (white blood cell, red blood cell, hemoglobin, and platelet counts) remained within normal reference ranges after treatment. A slight decrease in hemoglobin level was observed but was not clinically significant.Table 2Complete blood count results before and after treatmentComplete blood count parameterBaseline15 month post-treatmentNormal rangeWhite blood cell (109/L)6.346.063.5–9.5Red blood cell (1012/L)4.374.254.3–5.8Hemoglobin (g/L)144130130–175Platelet (109/L)235259100–300 Table 2Complete blood count results before and after treatmentComplete blood count parameterBaseline15 month post-treatmentNormal rangeWhite blood cell (109/L)6.346.063.5–9.5Red blood cell (1012/L)4.374.254.3–5.8Hemoglobin (g/L)144130130–175Platelet (109/L)235259100–300 Complete blood count results before and after treatment Comparison of post-treatment MRI with baseline images revealed notable improvements in both knee joints. Specifically, bone marrow edema demonstrated a marked reduction in size and intensity bilaterally. The suprapatellar bursal effusion and associated synovial hyperplasia were also significantly decreased. Regarding the articular cartilage, although the Outerbridge grade remained unchanged, morphological signs of improvement were evident. Furthermore, the left meniscal injury showed signs of resolution, and edema in the infrapatellar fat pad of the right knee had significantly resolved (Figs. 2, 3).Fig. 2Comparative MRI of the left knee before and 15 months after PRP injection.1a: Tear of the medial meniscus.1b: Chondral injury of the femoral condyle with associated subchondral bone marrow edema.1c: Suprapatellar effusion with thickening and elongation of the synovial plica.2a: Improvement of the medial meniscal tear (compared with 1a).2b: Improved osteochondral injury of the femoral condyle compared with 1b; note the evolution of subchondral bone marrow edema from a patchy to a speckled pattern.2c: Reduction in suprapatellar effusion (compared with 1c) with complete resolution of synovial plica thickening and elongationFig. 3Comparative MRI of the right knee before and 15 months after PRP injection. 1a: Osteochondral injury of the femoral condyle with subchondral bone marrow edema. 1b: Edema of the infrapatellar fat pad. 1c: Suprapatellar effusion. 2a: Improvement in osteochondral injury (compared with 1a), subchondral bone marrow edema has evolved from a patchy to a speckled pattern. 2b: Reduction in the extent and severity of infrapatellar fat pad edema (compared with 1b). 2c: Decreased suprapatellar effusion (compared with 1c) Comparative MRI of the left knee before and 15 months after PRP injection.1a: Tear of the medial meniscus.1b: Chondral injury of the femoral condyle with associated subchondral bone marrow edema.1c: Suprapatellar effusion with thickening and elongation of the synovial plica.2a: Improvement of the medial meniscal tear (compared with 1a).2b: Improved osteochondral injury of the femoral condyle compared with 1b; note the evolution of subchondral bone marrow edema from a patchy to a speckled pattern.2c: Reduction in suprapatellar effusion (compared with 1c) with complete resolution of synovial plica thickening and elongation Comparative MRI of the right knee before and 15 months after PRP injection. 1a: Osteochondral injury of the femoral condyle with subchondral bone marrow edema. 1b: Edema of the infrapatellar fat pad. 1c: Suprapatellar effusion. 2a: Improvement in osteochondral injury (compared with 1a), subchondral bone marrow edema has evolved from a patchy to a speckled pattern. 2b: Reduction in the extent and severity of infrapatellar fat pad edema (compared with 1b). 2c: Decreased suprapatellar effusion (compared with 1c) No significant treatment-related adverse events were reported or observed following the series of bilateral knee PRP injections. Summary of clinical course The patient commenced the PRP regimen with severe bilateral knee pain (NRS 7–8) and significant functional limitation (WOMAC 56–60). A rapid symptomatic response was observed following the initial series of weekly injections, with substantial reductions in pain and improvements in function evident at the 1-month follow-up. This positive trajectory continued throughout the treatment period, with further gains noted at 3, 6, and 9 months. By the final 15-month evaluation, the patient achieved optimal outcomes, with pain scores reduced to 1/10 bilaterally and WOMAC scores improved to 4, representing over 90% improvement from baseline. Knee range of motion normalized to 135°, and quality of life scores nearly doubled. Notably, this significant and sustained clinical improvement was supported by objective MRI findings at 15 months, which showed reduction in bone marrow edema and joint effusion, alongside improvement in the mensiscal tear. The entire 15-month course was well-tolerated without any reported adverse events. The key timeline of patient management and follow-up is shown in Table 3.Table 3Key timeline of patient management and follow-upRelative time (T)Key eventPrimary interventions and assessmentsT = 0 (Baseline)Initial Visit and Baseline AssessmentHistory taking, physical examination, bilateral knee MRI, baseline clinical scores (NRS, WOMAC, SF-12, etc.)T = 0 → 1 monthInitiation of PRP therapyCompletion of the initial 4 weekly ultrasound-guided bilateral intra-articular PRP injectionsT = 1 monthFirst follow-upClinical assessment: Pain (NRS), function (WOMAC, TAM), quality of life (SF-12), balance (BESS, TUG), etc. Significant improvement in all metrics compared to baseline was demonstratedT = 1 month → 15 monthsMaintenance phase of PRP therapyContinuation of biweekly bilateral intra-articular PRP injectionsT = 3 monthsSecond follow-upComprehensive clinical assessment, showing further symptomatic and functional improvement compared to the 1-month follow-upT = 9 monthsThird follow-upClinical assessment confirming sustained therapeutic efficacyT = 15 months (Final)Final treatment and comprehensive evaluationAdministration of the last PRP injection. Final comprehensive clinical assessment and bilateral knee MRI were performed for comparison with baseline images Table 3Key timeline of patient management and follow-upRelative time (T)Key eventPrimary interventions and assessmentsT = 0 (Baseline)Initial Visit and Baseline AssessmentHistory taking, physical examination, bilateral knee MRI, baseline clinical scores (NRS, WOMAC, SF-12, etc.)T = 0 → 1 monthInitiation of PRP therapyCompletion of the initial 4 weekly ultrasound-guided bilateral intra-articular PRP injectionsT = 1 monthFirst follow-upClinical assessment: Pain (NRS), function (WOMAC, TAM), quality of life (SF-12), balance (BESS, TUG), etc. Significant improvement in all metrics compared to baseline was demonstratedT = 1 month → 15 monthsMaintenance phase of PRP therapyContinuation of biweekly bilateral intra-articular PRP injectionsT = 3 monthsSecond follow-upComprehensive clinical assessment, showing further symptomatic and functional improvement compared to the 1-month follow-upT = 9 monthsThird follow-upClinical assessment confirming sustained therapeutic efficacyT = 15 months (Final)Final treatment and comprehensive evaluationAdministration of the last PRP injection. Final comprehensive clinical assessment and bilateral knee MRI were performed for comparison with baseline images Key timeline of patient management and follow-up Discussion The findings of this study demonstrate that ultrasound-guided long-term PRP injection may contribute to pain relief and improved joint function in patients with moderate-to-severe KOA. Moreover, the long-term injection regimen appeared to be safe and well-tolerated. Earlier investigations have demonstrated the efficacy of PRP in knee osteoarthritis. A meta-analysis by Shen et al. concluded that PRP significantly improved pain and function in patients with early-to-mid-stage KOA at 3, 6, and 12 months of follow-up [7]. In the context of severe KOA, Comlek et al. reported sustained symptom relief over 12 months in patients treated with a combination of stromal vascular fraction and PRP [8]. In the present study, we observed that patient with moderate-to-severe KOA who received multiple, ultrasound-guided PRP injections alone also exhibited improvements in pain and function. These findings appear to contrast with the prevailing consensus that PRP therapy is predominantly effective only for mild-to-moderate disease. Several factors may account for this divergence. First, the use of ultrasound guidance allowed for real-time monitoring of needle positioning and injectate dispersion, which may have enhanced precision and reduced procedure-associated risks and discomfort [9, 10]. Second, a long-term therapeutic regimen involving repeated administrations might better support the biological processes underlying tissue repair and regeneration. These technical and regimen-related factors may partly explain why, in contrast to the prevailing consensus, patients with moderate-to-severe KOA could still benefit from PRP therapy alone. The meniscus is a critical structure within the knee joint that provides mechanical load distribution and contributes to joint stability. However, its limited vascularity and poor nutritional supply make the repair of meniscal injuries a persistent clinical challenge [11]. PRP has emerged as a promising regenerative strategy for promoting meniscal healing. In addition to stimulating endogenous hyaluronic acid synthesis, PRP upon activation releases a variety of growth factors (e.g., TGF-β, VEGF, and PDGF) that facilitate chondrogenic differentiation and angiogenesis. These processes increase the local vascular supply, activate reparative mechanisms, and accelerate tissue regeneration [12]. Nonetheless, clinical outcomes have been inconsistent across studies: although Medina-Porqueres et al. reported significant improvements in pain, function, and quality of life following intra-articular PRP injection in patients with meniscal injury [13], a randomized controlled trial demonstrated that a single postoperative PRP injection did not improve short-term (6-month) recovery outcomes after partial meniscectomy [14]. In the present study, multiple PRP therapy was observed in conjunction with marked morphological improvements in meniscal integrity. While the underlying mechanisms remain to be fully elucidated, the long-term protocol adopted may have played a role. Although the cartilage lesion in this case maintained an Outerbridge grade IV classification, imaging revealed mild morphological and signal improvements, accompanied by a substantial reduction in bone marrow edema after 15 months of treatment. Previous studies suggest that PRP has limited efficacy in inducing structural repair in advanced cartilage defects [15]. A study by Bansal et al. demonstrated that PRP could slow cartilage degeneration in patients with mild-to-moderate KOA; however, the exclusion of severe cases limits the generalizability of these results [16]. Similarly, Zhang et al. reported that combination therapy with hyaluronic acid and PRP was more effective than hyaluronic acid alone in reducing bone marrow edema at 12 months; however, severe KOA patients were not included in the cohort [17]. In this study, despite the challenge of severe (grade IV) cartilage injury, an extended PRP regimen was associated with a significant reduction in bone marrow edema, modest radiological improvements, and, importantly, no progression of cartilage injury over 15 months. These findings suggest that prolonged PRP therapy may represent a promising clinical strategy for the management of advanced cartilage lesions. Moreover, MRI findings indicated a reduction in joint effusion and improved synovial conditions, potentially attributable to the high concentration of growth factors and anti-inflammatory mediators within PRP [18]. Upon intra-articular administration, PRP contributes to a regenerative microenvironment by increasing beneficial cytokine levels and suppressing inflammatory cascades [19, 20]. Specifically, the interleukin-1 receptor antagonist (IL-1Ra) present in PRP competitively inhibits IL-1β signaling and acts synergistically to downregulate tumor necrosis factor-alpha (TNF-α), leading to attenuated synovitis [21]. This anti-inflammatory mechanism is further corroborated by animal studies, in which PRP and its derivatives reduced the expression of proinflammatory factors, including matrix metalloproteinase-3 (MMP-3), TNF-α, IL-1β, and IL-6 while increasing the expression of tissue inhibitors of metalloproteinases (TIMPs), thereby mitigating extracellular matrix degradation and inflammatory damage [22]. These results further support the positive modulatory role of PRP in restoring joint homeostasis observed in the present study. The safety of PRP therapy is underpinned by its autologous nature, which minimizes immunogenic risks. Consistent with existing reports [23, 24], adverse events were mostly mild and transient, such as post-injection pain and swelling. Notably, in this study, no significant complications were observed throughout the 15-month bilateral treatment course. Moreover, all hematologic parameters, including RBC, WBC, platelet, and hemoglobin levels, remained stable before and after treatment, supporting the systemic safety of the long-term PRP regimen. A key limitation is the limited number of imaging timepoints available for evaluation. We fully acknowledge that in a case of moderate-to-severe knee osteoarthritis, the observed improvements could be partially attributable to the natural history of the disease, rather than the intervention itself. Furthermore, given the uncontrolled design, we cannot exclude the potential influence of concomitant lifestyle modifications or psychological factors, such as placebo effects. Notably, the patient's strong belief in the potential benefits of PRP may have contributed to a significant placebo effect, influencing the reported symptomatic outcomes. Conclusion In summary, the findings of this study suggest that ultrasound-guided long-term PRP injection protocol may represent a well-tolerated and potentially effective treatment for patients with moderate-to-severe knee osteoarthritis, associated with observed improvements in pain, function, and quality of life. Although these results provide a preliminary support for extended PRP treatment protocols in severe KOA, further validation through large-sample, prospective studies with extended follow-up are necessary to better assess its long-term benefits.